Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1B Open-Label Study of Crizotinib in Tumors With ALK Genetic Alterations (A8081013)
jRCT2080221425Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of crizotinib in cancer, anaplastic large cell lymphoma (ALCL) and inflammatory pseudotumor (IPT), sponsored by Pfizer. Primary endpoint: Safety and tolerability of crizotinib. Started Mar 2011; status: completed.
02
Drugs
crizotinib
03
Conditions
canceranaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)
Beyond the preview
Go deeper on jRCT2080221425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221425.